These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15599525)

  • 1. Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):723. PubMed ID: 15599525
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
    Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
    J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
    Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
    Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
    Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed therapy.
    Wong CY; Gates VL; Tang B; Campbell J; Qing F; Lewandowski RJ; Thie J; Ho CL; Savin M; Salem R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):233-6. PubMed ID: 20423237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET.
    Lin M; Shon IH; Wilson R; D'Amours SK; Schlaphoff G; Lin P
    Hepatogastroenterology; 2007; 54(75):910-2. PubMed ID: 17591090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease.
    Turkmen C; Ucar A; Poyanli A; Vatankulu B; Ozkan G; Basaran M; Serin K; Sanli Y; Adalet I
    Cancer Biother Radiopharm; 2013 Sep; 28(7):534-40. PubMed ID: 23647219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
    Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
    Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET.
    Wong CY; Salem R; Qing F; Wong KT; Barker D; Gates V; Lewandowski R; Hill EA; Dworkin HJ; Nagle C
    J Nucl Med; 2004 Nov; 45(11):1892-7. PubMed ID: 15534060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 90Y-PET for the assessment of microsphere biodistribution after selective internal radiotherapy.
    Bagni O; D'Arienzo M; Chiaramida P; Chiacchiararelli L; Cannas P; D'Agostini A; Cianni R; Salvatori R; Scopinaro F
    Nucl Med Commun; 2012 Feb; 33(2):198-204. PubMed ID: 22124359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance.
    Vouche M; Salem R; Miller FH; Lemort M; Vanderlinden B; De Becker D; Hendlisz A; Flamen P
    Clin Imaging; 2015; 39(3):454-62. PubMed ID: 25724225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
    van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
    J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.
    Soydal C; Kucuk ON; Gecim EI; Bilgic S; Elhan AH
    Nucl Med Commun; 2013 May; 34(5):501-6. PubMed ID: 23478586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases.
    Rosenbaum CE; van den Bosch MA; Veldhuis WB; Huijbregts JE; Koopman M; Lam MG
    Eur Radiol; 2013 Apr; 23(4):931-7. PubMed ID: 23111818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver.
    Edalat F; Camacho JC; Kokabi N; Kendi AT; Galt JR; Kim HS
    Clin Nucl Med; 2016 Feb; 41(2):e76-81. PubMed ID: 26447380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
    Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
    AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response.
    Tochetto SM; Töre HG; Chalian H; Yaghmai V
    AJR Am J Roentgenol; 2012 May; 198(5):1093-9. PubMed ID: 22528898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.